ATX 3 279 -1,0%  Dow 24 652 0,6%  Nasdaq 6 466 1,2%  Euro 1,1750 -0,1% 
ATX P 1 656 -0,9%  EStoxx50 3 561 0,1%  Nikkei 22 553 -0,6%  CHF 1,1646 0,0% 
DAX 13 104 0,3%  FTSE100 7 491 0,6%  Öl 63,3 -0,2%  Gold 1 245 -0,5% 

Cancer Genetics Aktie [WKN DE: A1W4HC / ISIN: US13739U1043]

07.12.2017 13:51:32

Cancer Genetics Buy

Der Analyst Maxim Group hat die Einstufung für Cancer Genetics Inc auf "Buy" mit einem Kursziel von 6 USD belassen.
Zusammenfassung: Cancer Genetics Inc Buy
Unternehmen:
Cancer Genetics Inc
Analyst:
Maxim Group
Kursziel:
$ 6,00
Rating jetzt:
Buy
Kurs*:
1,79 €
Abst. Kursziel*:
235,57%
Rating update:
initiated
Kurs aktuell:
$ 1,95
Abst. Kursziel aktuell:
207,69%
Analyst Name::
-
KGV*:
-
* Zum Zeitpunkt der Analyse

Analysen zu Cancer Genetics Inc

mehr Analysen
  • Alle
  • Buy
  • Hold
  • Sell
07.12.17 Cancer Genetics Buy Maxim Group
27.06.17 Cancer Genetics Buy Dawson James Securities
26.06.17 Cancer Genetics Speculative Buy The Benchmark Company
26.09.16 Cancer Genetics Buy Rodman & Renshaw, LLC

Eintrag hinzufügen

Aktien in diesem Artikel

Cancer Genetics Inc 1,65 -0,30% Cancer Genetics Inc
Aktuelle Aktienanalysen
15.12.17 Siemens Neutral JP Morgan Chase & Co.
15.12.17 Oracle Sector Perform RBC Capital Markets
15.12.17 S&P Global overweight Barclays Capital
15.12.17 Sanderson Farms Equal weight Barclays Capital
15.12.17 Taubman Centers Market Perform BMO Capital Markets
15.12.17 Penumbra Market Perform BMO Capital Markets
15.12.17 Abbott Laboratories Outperform BMO Capital Markets
15.12.17 Progressive Waste Solutions Outperform BMO Capital Markets
15.12.17 Magellan Midstream Partners LP Outperform BMO Capital Markets
15.12.17 scPharmaceuticals Outperform BMO Capital Markets
15.12.17 Sonoco Products Equal weight Barclays Capital
15.12.17 Sealed Air overweight Barclays Capital
15.12.17 Hi-Crush Partners LP Partnership Interest Equal weight Barclays Capital
15.12.17 Windstream Underweight Barclays Capital
15.12.17 Frontier Communications Underweight Barclays Capital
15.12.17 CenturyLink Equal weight Barclays Capital
15.12.17 Intra-Cellular Therapies Buy Canaccord Adams
15.12.17 Biohaven Pharmaceutical Buy Canaccord Adams
15.12.17 Siemens buy Joh. Berenberg, Gossler & Co. KG (Berenberg Bank)
15.12.17 Adobe Hold Pivotal Research Group
15.12.17 Oracle Conviction Buy List Goldman Sachs Group Inc.
15.12.17 O Reilly Automotive Neutral Wedbush Morgan Securities Inc.
15.12.17 Sovran Self Storage Sell UBS AG
15.12.17 Entegris Buy Seaport Global Securities
15.12.17 Foot Locker Buy Canaccord Adams
15.12.17 Wayfai a Buy Stifel, Nicolaus & Co., Inc.
15.12.17 Under Armour Buy Stifel, Nicolaus & Co., Inc.
15.12.17 Fitbit Sell Stifel, Nicolaus & Co., Inc.
15.12.17 CROCS Buy Stifel, Nicolaus & Co., Inc.
15.12.17 Juniper Networks Hold Stifel, Nicolaus & Co., Inc.
15.12.17 Cisco Hold Stifel, Nicolaus & Co., Inc.
15.12.17 Arista Networks Buy Stifel, Nicolaus & Co., Inc.
15.12.17 Nordson Hold Gabelli & Co
15.12.17 21st Century Fox (A) Market Perform Telsey Advisory Group
15.12.17 Nike buy Stifel, Nicolaus & Co., Inc.
15.12.17 Coca-Cola Neutral JP Morgan Chase & Co.
15.12.17 Stabilus Hold Kepler Cheuvreux
15.12.17 Aurubis (ex Norddeutsche Affinerie) buy Kepler Cheuvreux
15.12.17 Continental buy Kepler Cheuvreux
15.12.17 FormFactor Strong Buy Needham & Company, LLC
15.12.17 Aurubis (ex Norddeutsche Affinerie) kaufen Norddeutsche Landesbank (Nord/LB)
15.12.17 Deutsche Bank Halten Norddeutsche Landesbank (Nord/LB)
15.12.17 Johnson Outdoors Outperform Imperial Capital
15.12.17 Solaris Oilfield Infrastructur a Outperform Imperial Capital
15.12.17 Adobe Outperform BMO Capital Markets
15.12.17 Oracle Outperform BMO Capital Markets
15.12.17 Valeant Pharmaceuticals International Underperform Mizuho
15.12.17 Costco Wholesale Outperform Telsey Advisory Group
15.12.17 Delta Air Lines Outperform Cowen and Company, LLC
15.12.17 Cardiovascular Systems Hold Needham & Company, LLC